Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence
Salvatore Perrone, Matteo Molica, Diana Giannarelli, Giada Pacitto, Simone Ferrero · 2026
Read Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence by Salvatore Perrone, Matteo Molica, Diana Giannarelli, Giada Pacitto, Simone Ferrero (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13550457.txt.
Description
Salvatore Perrone and colleagues pool trials and real-world studies of a modern frontline regimen for diffuse large B-cell lymphoma, in a 2026 systematic review and meta-analysis. The Pola-R-CHP combination, which swaps one drug of the classic cocktail for an antibody-drug conjugate, became standard after a landmark trial. Pooling two randomized trials and ten real-world series covering 3,472 patients, the team compared complete response and survival between the two evidence worlds.
Complete responses pooled at seventy-eight percent, with real-world studies actually reporting higher rates than the trials. One-year survival without progression also ran slightly higher in practice, while overall survival matched. Differences between studies were large, yet age, risk score, and cell subtype did not explain them. The authors conclude the regimen's trial performance holds up in the clinic.
Catalog record
| CREATOR | Salvatore Perrone, Matteo Molica, Diana Giannarelli, Giada Pacitto, Simone Ferrero |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25137 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |